Oxford Cannabinoid Technologies "ready to go" after phase 1 trial submission

Video
Written By Rob Bennett

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) chief scientific officer Dr Valentino Parravicini speaks to Proactive after submitting a phase 1 trial application for its lead programme (OCT461201) to the UK Medicines & Healthcare products Regulatory Agency (MHRA) and Wales Research Ethics Committee (REC). Parravicini says that the submission demonstrates that the company is "ready to go" in 2023. 

Rob Bennett https://www.oxcantech.com
Previous

Dr Valentino Parravicini: Oxford Cannabinoid Submit Clinical Trial Application
Next

Oxford Cannabinoid Technologies nearly ready for new Phase 1 trial